Diagnosis and Treatment of Prostatic Sarcoma: Advances in the Understanding of a Rare and Aggressive Disease
Main Article Content
Abstract
Prostatic sarcoma is a rare and aggressive disease that accounts for less than 1% of all diagnosed malignant prostate tumors. It mainly affects older men and its epidemiology is still not well defined due to the lack of comprehensive registries. The clinical presentation of prostatic sarcoma is variable, with urinary symptoms, pelvic or lumbar pain and systemic symptoms. Diagnosis requires a comprehensive evaluation including clinical history, physical examination, prostate biopsy and imaging studies. Treatment is individualized and multidisciplinary, including surgery, radiotherapy, chemotherapy and targeted therapies. However, due to the rarity of this disease, evidence on the efficacy of different treatments is limited. More research is needed to better understand prostatic sarcoma, develop more effective therapeutic strategies and improve outcomes for affected patients.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Janet NL, May A-W, Akins RS. Sarcoma of the prostate: a single institutional review. Am J Clin Oncol. 2009;32(1):27-9. Doi: https://doi. org/10.1097/COC.0b013e31817b6061
II. González González Jose Luis, Menéndez Núñez Joaquín, Rassi Diana. Giant prostatic stromal sarcoma. Rev Cubana Cir [Internet]. 2013 Jun [cited 2023 Jun 12] ; 52( 2 ): 146-153. Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-74932013000200008&lng=es.
III. Wu H-Y, Snyder HM, Womer RB. Genitourinary rhabdomyosarcoma: which treatment, how much, and when? J Pediatr Urol. 2009; 5(6):501-6. Doi: https://doi. org/10.1016/j.jpurol.2009.06.011.
IV. Oscar García J, Alfaro Ferredes L, Ruiz Cerdá J, Cuñat Albert E, Martínex Jabal-oyas J, Jímenez Cruz J. Leiomyosarcoma of the prostate. Arch Esp Urol. 1993; 46(9):831-3.
V. Gaudin PB, Rosai J, Epstein JI. Sarcomas and related proliferative lesions of specialized prostatic stroma: a clinicopathologic study of 22 cases. Am J Surg Pathol. 1998;22(2):14862. doi: https://doi.org/10.1097/00000478199802000-00002
VI. Navarro-Vargas Juan Carlos.Sarcoma of the prostate filodes type. Revista Mexicana de Urología.Rev Mex Urol 2012;72(4):211-215https://www.elsevier.es/es-revista-revista-mexicana-urologia-302-articulo-sarcoma-prostata-tipo-filodes-X2007408512543229
VII. Delahunt B, Eble JN, Nacey JN, Grebe SK. Sarcomatoid carcinoma of the prostate: progression from adenocarcinoma is associated with p53 over-expression. Anticancer Res. 1999 Sep-Oct;19(5B):4279-83. PMID: 10628387.
VIII. Prendergast NJ, Atkins MR, Schatte EC, Paulson DF, Walther PJ. P53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma. J Urol. 1996 May; 155(5):1685-92. PMID: 8627854.
IX. Ethat NT, Chuong L, Dickman J, Deng T, Chang G, Hwang J. Prostate sarcoma. IJU Case Rep. 2023 Mar 12;6(3): 165-168. Doi 10.1002/iju5.12578.PMID: 37144084; PMCID: PMC10151200.
X. Markowski MC, Eisenberger MA, Zahurak M, Epstein JI, Paller CJ. Sarcomatoid Carcinoma of the Prostate: Retrospective Review of a Case Series from the Johns Hopkins Hospital. Urology. 2015; 86(3):539-43. Doi: https://doi. org/10.1016/j.urology.2015.06.011.
XI. Rodrigues DN, Hazell S, Miranda S, Crespo M, Fisher C, de Bono JS, et al. Sarcomatoid carcinoma of the prostate: ERG fluorescence in-situ hybridization confirms epithelial origin. Histopathology. 2015;66(6):898-901. doi: https://doi.org/10.1111/his.12493
XII. Tauchi K, Tsutsumi Y, Yoshimura S, Watanabe K. Immunohistochemical and immunoblotting detection of cytokeratin in smooth muscle tumors. Acta Pathol Jpn. 1990; 40(8):574-80.
XIII. Norton AJ, Thomas JA, Isaacson PG. Cytokeratin-specific monoclonal antibodies are reactive with tumours of smooth muscle derivation. An immunocytochemical and biochemical study using antibodies to intermediate filament cytoskeletal proteins. Histopathology. 1987; 11(5):487-99. Doi: https://doi.org/10.1111/j.1365-2559.1987. tb02657.x
XIV. Zhang Q, Wang H, Ren L, Qi X, Liu F, Zhang D. Primary synovial sarcoma of the prostate metastatic to the liver and lung: a case report. World J Surg Oncol. 2014; 12:194.] Available from: https://www.ncbi. nlm.nih.gov/pmc/articles/PMC4086276/
XV. Muglia VF, Saber G, Maggioni G, Monteiro AJC. MRI findings of prostate stromal tumour of uncertain malignant potential: a case report. Br J Radiol. 2011; 84(1006):e194-196. doi: https:// doi.org/10.1259/bjr/67699443.
XVI. Rojas-Jiménez A, Otero-Garcia M, MateosMartin A. Stromal prostatic sarcoma: a rare tumor with rare clinical and imaging presentation. J Radiol Case Rep. 2013;7(7):2431. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC3888162/
XVII. Tamada T, Sone T, Miyaji Y, Kozuka Y, Ito K. MRI Appearance of Prostatic Stromal Sarcoma in a Young Adult. Korean J Radiol. 2011;12(4):519-23. Available from: https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3150682/
XVIII. González González Jose Luis, Menéndez Núñez Joaquín, Rassi Diana. Giant prostatic stromal sarcoma. Rev Cubana Cir [Internet]. 2013 Jun [cited 2023 Jun 12]; 52(2 ): 146-153. Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-74932013000200008&lng=es.